CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Up 87.5% in December

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 6,000 shares, a growth of 87.5% from the December 15th total of 3,200 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average trading volume of 14,500 shares, the short-interest ratio is currently 0.4 days.

Analysts Set New Price Targets

Several research analysts have commented on CLGN shares. D. Boral Capital restated a “buy” rating and set a $14.00 price objective on shares of CollPlant Biotechnologies in a research report on Wednesday, November 27th. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of CollPlant Biotechnologies in a report on Friday, November 29th.

CollPlant Biotechnologies Stock Performance

Shares of CLGN traded up $0.16 during mid-day trading on Thursday, reaching $4.14. The company had a trading volume of 674 shares, compared to its average volume of 6,837. CollPlant Biotechnologies has a 1-year low of $3.24 and a 1-year high of $6.75. The company has a market capitalization of $47.35 million, a price-to-earnings ratio of -2.69 and a beta of 0.63. The company’s 50 day simple moving average is $3.98 and its 200 day simple moving average is $4.45.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in CollPlant Biotechnologies stock. Benjamin Edwards Inc. acquired a new position in shares of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 23,810 shares of the company’s stock, valued at approximately $112,000. Benjamin Edwards Inc. owned about 0.21% of CollPlant Biotechnologies as of its most recent SEC filing. Institutional investors and hedge funds own 21.69% of the company’s stock.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.